BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10220124)

  • 1. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.
    Poyurovsky M; Isakov V; Hromnikov S; Modai I; Rauchberger B; Schneidman M; Weizman A
    Int Clin Psychopharmacol; 1999 Mar; 14(2):95-100. PubMed ID: 10220124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients.
    Poyurovsky M; Hermesh H; Weizman A
    Clin Neuropharmacol; 1996 Aug; 19(4):305-13. PubMed ID: 8828993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J; Kaplan Z; Benjamin J
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
    Poyurovsky M; Dorfman-Etrog P; Hermesh H; Munitz H; Tollefson GD; Weizman A
    Int Clin Psychopharmacol; 2000 May; 15(3):169-73. PubMed ID: 10870875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia.
    Poyurovsky M; Hramenkov S; Isakov V; Rauchverger B; Modai I; Schneidman M; Fuchs C; Weizman A
    Psychiatry Res; 2001 May; 102(1):49-57. PubMed ID: 11368839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder.
    Poyurovsky M; Faragian S; Shabeta A; Kosov A
    Psychiatry Res; 2008 May; 159(1-2):133-9. PubMed ID: 18406469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.
    Feenstra MGP; Klompmakers A; Figee M; Fluitman S; Vulink N; Westenberg HGM; Denys D
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):310-319. PubMed ID: 26712326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.